[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628608":3},{"organization":4,"outcomesModule":7,"designInfo":42,"detailedDescription":11,"studyPopulation":11,"armGroups":52,"interventions":85,"overallOfficials":99,"centralContacts":103,"locations":111,"responsibleParty":125,"collaborators":11,"id":127,"slug":11,"hasResults":128,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":11,"eligibilityCriteria":132,"healthyVolunteers":128,"sex":133,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":11,"studyType":139,"phases":140,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":114,"whyStopped":11,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":157},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":18,"otherOutcomes":11},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Part A: Frequency of Adverse Events (AEs)",null,"Up to 12 months",{"measure":14,"description":11,"timeFrame":15},"Part B: Percent Change from Baseline in Body Weight","Baseline up to Month 6",{"measure":17,"description":11,"timeFrame":15},"Part C: Percent Change from Baseline in Body Weight",[19,22,25,27,29,32,34,37,39],{"measure":20,"description":11,"timeFrame":21},"Part A: Change from Baseline in Proteins in Adipose Tissue","Baseline up to Month 12",{"measure":23,"description":11,"timeFrame":24},"Part A: Area Under the Plasma Concentration-time Curve (AUC) of ALN-2232 in Plasma","Predose and up to 15 days postdose",{"measure":26,"description":11,"timeFrame":24},"Part A: Maximum Observed Plasma Concentration (Cmax) of ALN-2232 in Plasma",{"measure":28,"description":11,"timeFrame":24},"Part A: Time to Maximum Plasma Concentration (Tmax) of ALN-2232 in Plasma",{"measure":30,"description":11,"timeFrame":31},"Part A: Fraction of ALN-2232 excreted in urine","Predose and up to 8 days postdose (fe)",{"measure":33,"description":11,"timeFrame":21},"Part A: Percent Change from Baseline in Body Weight",{"measure":35,"description":11,"timeFrame":36},"Part B and Part C: Concentrations of ALN-2232 in Plasma","Predose and up to 6 months postdose",{"measure":38,"description":11,"timeFrame":21},"Part B and Part C: Percent Change from Baseline in Body Weight",{"measure":40,"description":41,"timeFrame":21},"Part B and Part C: Change from Baseline in Body Fat Mass and Lean Mass","Measured by dual x-ray absorptiometry (DXA)",{"allocation":43,"interventionModel":44,"interventionModelDescription":11,"primaryPurpose":45,"observationalModel":11,"timePerspective":11,"maskingInfo":46},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":47,"maskingDescription":11,"whoMasked":48},"TRIPLE",[49,50,51],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR",[53,59,65,69,73,77,80],{"label":54,"type":55,"description":56,"interventionNames":57},"Part A: ALN-2232","EXPERIMENTAL","Participants will be administered a single dose of ALN-2232",[58],"Drug: ALN-2232",{"label":60,"type":61,"description":62,"interventionNames":63},"Part A: Placebo","PLACEBO_COMPARATOR","Participants will be administered a single dose of placebo",[64],"Drug: Placebo",{"label":66,"type":55,"description":67,"interventionNames":68},"Part B: ALN-2232","Participants will be administered multiple doses of ALN-2232",[58],{"label":70,"type":61,"description":71,"interventionNames":72},"Part B: Placebo","Participants will be administered multiple doses of placebo",[64],{"label":74,"type":55,"description":67,"interventionNames":75},"Part C: ALN-2232",[58,76],"Drug: Tirzepatide",{"label":78,"type":61,"description":71,"interventionNames":79},"Part C: Placebo",[64],{"label":81,"type":82,"description":83,"interventionNames":84},"Part C: Tirzepatide","OTHER","Participants will be administered multiple doses of tirzepatide once weekly",[76],[86,91,95],{"type":87,"name":88,"description":89,"armGroupLabels":90,"otherNames":11},"DRUG","ALN-2232","ALN-2232 will be administered subcutaneously (SC)",[54,66,74],{"type":87,"name":92,"description":93,"armGroupLabels":94,"otherNames":11},"Placebo","Placebo will be administered SC",[60,70,78],{"type":87,"name":96,"description":97,"armGroupLabels":98,"otherNames":11},"Tirzepatide","Tirzepatide will be administered SC",[74,81],[100],{"name":101,"affiliation":5,"role":102},"Medical Director","STUDY_DIRECTOR",[104,109],{"name":105,"role":106,"phone":107,"phoneExt":11,"email":108},"Alnylam Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":105,"role":106,"phone":110,"phoneExt":11,"email":108},"1-877-256-9526",[112],{"facility":113,"status":114,"city":115,"state":11,"zip":116,"country":117,"countryCode":118,"cosmosGeoPoint":119,"geoPoint":124,"contacts":11},"Clinical Trial Site","RECRUITING","Mount Royal","H3P 3P1","Canada","CA",{"type":120,"coordinates":121},"Point",[122,123],-73.64918,45.51675,{"lat":123,"lon":122},{"type":126,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100628608",false,"NCT07463846","A Study to Evaluate ALN-2232 in Participants With Obesity","A Phase 1\u002F2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-2232 as Monotherapy and Co-initiated With Tirzepatide in Adult Participants With Obesity","Inclusion Criteria:\n\nAll Parts:\n\n* Has a body mass index (BMI) of ≥30 kg\u002Fm\\^2 and \\\u003C40 kg\u002Fm\\^2\n* Has a hemoglobin A1c (HbA1c) \\\u003C6.5%\n\nExclusion Criteria:\n\nAll Parts:\n\n* Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results\n* Receiving therapies for chronic weight management or antidiabetic medications\n\nNote: other protocol defined inclusion\u002Fexclusion criteria apply","ALL","18 Years","65 Years",{"count":137,"type":138},156,"ESTIMATED","INTERVENTIONAL",[141,142],"PHASE1","PHASE2","The purpose of this study is to:\n\n* evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity\n* evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity\n* evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity",[145],"Obesity",[147],"siRNA, RNAi therepeutic","2026-06-10",{"date":150,"type":151},"2026-06-12","ACTUAL",{"date":153,"type":151},"2026-03-02",{"date":155,"type":138},"2028-03-02",{"name":5,"class":6},1]